Purpose/Objective: Three dimensional image-guided brachytherapy allows the assessment of the dose to organs at risk with Dose Volume Histograms (DVHs). The purpose of this study was to find a correlation between the DVHs and in-vivo dosimetry measurements for the bladder and rectum. Materials and Methods: During the period from 2009 to 2011, a total of 17 cervix carcinoma patients were treated with High Dose Rate brachytherapy . After the implantation of the catheter and previous to the treatment, the patients were CT scanned generating a total of 28 CT datasets. In-vivo dosimetry was performed 2 to 3 times on each patient using Thermo Luminescence Dosimeters of LiF (TLD-100). The TLD rods were inserted in plastic tubes and separated with wires to facilitate their location on the CT scan. The tubes were introduced in urethral and rectal catheters inside the patient. The TLDs were calibrated every treatment day using the same Ir-192 source that was used for the treatment. Protocols of annealing and read-out were followed to reduce uncertainties in dose measurements around brachytherapy sources. A retrospective study of these patients was performed after the acquisition of the brachytherapy dose planning system, Oncentra R Brachy v4.0. The 28 CT datasets were imported in the dose planning system, the bladder and rectum delineated, a dose plan reproducing the received treatment was generated and the DVHs calculated. The minimum dose to 5cc, 2cc, 1cc and 0.1cc tissue receiving the highest dose (D 5cc , D 2cc , D 1cc and D 0.1cc ) was recorded and correlated to the maximum and average dose measured with the TLDs. Results: Statistically significant correlation (p<0.001) was found between the bladder volumetric doses (D 5cc , D 2cc , D 1cc and D 0.1cc ) and the measured maximum and average dose. The correlation coefficients were 0.83, 0.85, 0.87 and 0.87 respectively for the maximum dose and 0.84, 0.86, 0.86 and 0.85 respectively for the average dose. For the rectal data no statistically significant correlation was found (p<0.3). The correlation coefficients were 0.39, 0.39, 0.38, 0.34 respectively for the maximum dose and 0.15, 0.15, 0.14, 0.13 respectively for the average dose. Conclusions: The significant correlation between the volumetric bladder doses and the measurements indicate that in-vivo dosimetry is an important method of quality assurance and could be used as a complement to the 3D image-guided brachytherapy. The lack of correlation in the rectal data might be due to the length of the rectal catheter that reached the sigmoid area when it was fully inserted. Therefore the rectal measurements correspond to the sigmoid dose and not to the rectal dose. As a result of this study we started to use a shorter catheter to assure that the TLDs are located at the rectum.
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PO-0963 Thulium-170 for Brachytherapy G. Shani 1 1 Ben Gurion University, Biomedical Engineering, Beer Sheva, Israel Purpose/Objective: HDR brachytherapy is widely used for tumor treatment. The main disadvantage is that using Ir-192 requires heavily shielded treatment room with an expensive remote control room. The main purpose of this work is to develop a HDR brachytherapy source that can be used in every regular hospital operation room without the need of very expensive treatment and control rooms.We have found Tm-170 to be a suitable isotope for that purpose. We have manufactured many Tm-170 seeds and we present here the results of animal experiments and dosimetry of those Tm-170 sources. Materials and Methods: Thulium-170 (Tm-170) is a radioactive isotope of half-life128 days, emitting photons in the range of 7-84 keV (~11% of the radiation emitted) and two beta rays of energy E max = 880 keV 24%, and E max = 970 keV 76%. Many Tm-170 seeds for the LDR treatment were made and one source for the HDR treatment. The LDR seeds were made of thulium rectangles of dimensions: 4 x 0.6 x 0.2 mm or cylindrical of 0.6 mm diameter, 4 mm long. The thulium was inserted into titanium sealed tube of 0.8 mm od, 0.7 mm id and 7 mm long. LDR experiments were done with seed activity in the range 0.5-2.5 mCi. The HDR source was made of thulium cylinder 0.6 diameter 5 mm long inside a titanium tube, all in a stainless steel tube of 1.2 mm od, 1.0 mm id. It was activated to about 5 Ci. Dosimetry of the Tm 170 sources was done using a number of different methods and was calculated with Monte Carlo codes. TLD and film dosimetry were done in a Perspex phantom, in the range 4 -30 mm from the source center. Measurements with LUDLUM NaI(Tl) dosimeter were done in air. 80 BALB/C mice carrying KHJJ tumor were used in the LDR experiments and 12 Lewis rats carrying CNS1 Rat brain tumor were used in the HDR experiments Results: Survival of the treated animals is as follows: 60% of the treated mice were fully cured compared to none of the control, 75% of the rats were fully cured compared to none of the control. Dosimetry yielded the following results: The average of the many dose measurements of both the LDR seeds and the HDR source at 1 cm from the source (seed) in a Perspex phantom was 236 cGy/h Ci. That is about 20 times smaller than the dose from Ir-192 source at 1 cm. When theTm-170 seed is wrapped with 0.1 mm thick gold foil, to remove the beta radiation, the photon dose at 1 cm is reduced by a factor of 2. Conclusions: The survival of the treated animals is very encouraging, in particular for the HDR experiments. As for the dosimetry, Tm-170 yields a lower photon dose at 1 cm from the source than Ir-192, however, if the beta radiation is acceptable, than the dose in the range up to 3 mm from the source is higher for Tm-170 than for Ir-192. To avoid hot spots near the source the beta can be partly remove by wrapping the source with a thin gold coat. The Tm-170 activity should be higher and the seeds can be implanted at distances smaller than 1 cm. The benefit of avoiding heavy shielding worth the effort. Purpose/Objective: Robust and relevant quality control (QC) is essential to ensure accuracy and safety in radiotherapy. QC in HDR brachytherapy has not kept pace with clinical modernisation e.g. volume-based prescriptions and patient-specific inverse-optimisation. New QC standards are required to confirm dose distribution accuracy and avoid errors. Typical QC is currently limited to straight catheters, point doses and well chambers. A 'state of the art' practical implementation of advanced multichannel film dosimetry is presented to verify delivered dose distributions around treatment applicators and sources. 3 cases are presented; a cervix ring applicator, a shielded vaginal cylinder, and an isolated source catheter. The application of gamma assessment criteria in brachytherapy is discussed. Materials and Methods: A film-array water phantom was used to accurately position Gafchromic EBT3 film, cut to 12 x 12 cm. Multichannel film dosimetry separating dose-dependent and dose-
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